The prognostic value of multiorgan metastases in patients with non-small cell lung cancer and its variants: a SEER-based study
- 182 Downloads
This study aimed to investigate the prognostic value of different organs metastases in patients with non-small cell lung cancer (NSCLC) and its most common subtypes.
We identified 45,423 NSCLC cases (25,129 men and 20,294 women) between 2010 and 2013 with distant metastases, with complete clinical information obtained from the surveillance, epidemiology, and end results (SEER) database.
Bone and liver were the most and the least common metastatic sites with rates of 37.1 and 16.8%, respectively. The mortality rates associated with bone, brain, liver, lung metastases, and multiorgan metastases (MOM) were 73.2, 72.7, 78.3, 65.4, and 77.5%, respectively. Kaplan–Meier analyses demonstrated that patients with MOM and liver metastasis had the worst survival. Compared with NSCLC cases with other organ metastasis, but without the four organs metastasis, hazard ratios (HRs) for lung, bone, brain, and liver metastases, and MOM were 0.906 (95% CI 0.866–0.947), 1.276 (95% CI 1.225–1.330), 1.318 (95% CI 1.260–1.379), 1.481 (95% CI 1.388–1.580), and 1.647 (95% CI 1.587–1.709), respectively. Similar results were obtained for adenocarcinoma (AD) cases.
The mortality risk is highest with MOM and liver metastasis followed by bone, brain, other organ, and lung metastases in NSCLC and AD which is the most common variant for NSCLC. These results will be helpful for pre-treatment evaluation regarding the prognosis of NSCLC patients.
KeywordsNon-small cell lung cancer Metastasis Prognosis SEER
We would like to thank all the staff of National Cancer Institute for their efforts toward the SEER program.
Conception and design: Y.H., J.Y., and G.J.; acquisition, statistical analysis or interpretation of the data: all authors; drafting of the manuscript: Y.H., J.Y., Y.Z. and X.S.; all authors reviewed and approved the final version of the manuscript.
This work was supported by National Natural Science Foundation of China, No. 81600052 (J.Y.) and 81500052 (Y.Z.). This work was also supported by Shanghai Tenth Hospital’s improvement plan for National Natural Science Foundation of China, No. SYGZRPY (Y.H.).
Compliance with ethical standards
Conflict of interest
The authors disclose no potential conflicts of interest related to this study.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is waived.
- Goldstraw P et al (2007) The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2:706–714. https://doi.org/10.1097/JTO.0b013e31812f3c1a CrossRefPubMedGoogle Scholar